Lion's Mane for Motor Neuron Disease: Preclinical Evidence

ALS & Motor Neuron Disease

0 ALS studies

The 2024 ALSUntangled review found no studies of lion's mane in ALS cell models, animal models, or humans, while identifying five mechanisms theoretically relevant to motor neuron survival.

Muhanna et al., Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2024

NGF, BDNF, NT-3

neurotrophins lion's mane activates in non-ALS preclinical models

Erinacines

BBB-crossing mycelium compounds driving central neurotrophin activation

Peripheral nerves

where lion's mane motor nerve regeneration evidence is strongest

Muhanna et al., Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2024

View as image ↗

Whether lion's mane has any bearing on ALS was formally reviewed by the ALS medical community in 2024. A paper published in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, the field's leading specialty journal, reached a clear answer on the evidence: no studies of lion's mane exist in ALS cell models, ALS animal models, or ALS patients.^[1] Zero.

That is the complete answer to whether lion's mane motor neuron disease research has been conducted for ALS specifically. It hasn't. The more complicated question is whether that absence of evidence makes the science irrelevant. The same review argues it doesn't. Five biological pathways through which lion's mane exerts neuroprotective effects in other models align closely with the processes that kill motor neurons in ALS. Research on mushrooms and brain health increasingly positions lion's mane as the most mechanistically relevant medicinal mushroom for neurodegenerative disease. But for ALS specifically, the gap between mechanism and evidence is large, and that gap is honest.

What ALS Does to Motor Neurons (and Why Treatments Keep Failing)

ALS (amyotrophic lateral sclerosis) kills two populations of motor neurons simultaneously. Upper motor neurons run from the brain's motor cortex down through the brainstem to the spinal cord. Lower motor neurons run from the spinal cord out to the muscles. ALS destroys both, severing the brain's ability to send movement signals to voluntary muscles one region at a time. Most people progress from diagnosis to loss of mobility, speech, swallowing, and breathing within two to five years.

The biology is difficult because at least five distinct pathological processes happen at the same time. A protein called TDP-43, which normally helps organize how genes are read inside neurons, misfolds and forms toxic clumps inside motor neurons in roughly 97% of ALS cases. A protective enzyme called SOD1, which normally neutralizes free radicals before they damage cells, is disabled by mutations in about 20% of inherited ALS, leaving motor neurons exposed to runaway oxidative damage. The brain's immune cells, called microglia, shift into an overactivated state and release inflammatory signals that accelerate motor neuron death rather than prevent it. The cells' own power generators, called mitochondria, fail early in the ALS disease process, and motor neurons are more energy-dependent than almost any other cell type. Finally, the brain's main excitatory signaling chemical builds up around motor neurons and overstimulates them to death.

Two medications are approved. Riluzole extends survival by an average of three months. Edaravone slows functional decline in a subset of patients. Neither addresses the underlying pathology; they slow the decline at its margins. In this context, where a terminal disease has minimal therapeutic options, ALS patients and caregivers actively search for alternatives, and the mechanistic profile of lion's mane draws serious attention. For an overview of all mushroom compounds with ALS-relevant research, see mushrooms and ALS: emerging neuroprotective research.

The ALSUntangled Verdict: Zero ALS Evidence, but Five Relevant Mechanisms

The ALSUntangled group is a team of ALS neurologists and researchers who publish systematic evidence reviews in the ALS specialty journal, evaluating alternative therapies that ALS patients are actually using. In 2024, they reviewed lion's mane.^[1]

Their finding on the evidence question was unambiguous: no studies of lion's mane or its bioactive compounds have been conducted in ALS cell lines, ALS animal models, or ALS patients. Not a small number of studies. Zero.

What the review does not do is dismiss lion's mane as scientifically irrelevant. Muhanna and colleagues worked through the biological plausibility question systematically. Lion's mane stimulates nerve growth factor (NGF), a signaling protein that keeps neurons alive and maintains axon connections. It reduces neuroinflammation in neural tissue models. It shows antioxidant activity in pathways relevant to the oxidative stress damage that drives ALS. It blocks the programmed cell death cascade, called apoptosis, that motor neurons undergo in ALS. These are not marginal mechanisms. They target the core processes killing motor neurons.^[1]

The ALSUntangled framework evaluates alternative therapies on four dimensions: biological plausibility, preclinical evidence, clinical evidence, and safety. For lion's mane, plausibility is high, preclinical evidence exists in non-ALS models, clinical evidence is absent, and safety appears reasonable. Their conclusion: not enough evidence to recommend lion's mane for ALS, and the appropriate next step is ALS-specific preclinical research, which has not yet been funded or conducted.

This is the most honest single summary of where the science stands: mechanistically interesting, evidentially unproven for ALS specifically, and apparently safe.

The Five Ways Lion's Mane Targets Biology That ALS Disrupts

A 2023 review in the International Journal of Molecular Sciences by Szućko-Kociuba and colleagues mapped the neuroprotective mechanisms of lion's mane comprehensively; the five pathways they identified correspond directly to the five ALS disease processes described above.^[2]

NGF stimulation via hericenones. Hericenones are bioactive compounds found in the fruiting body of lion's mane. They stimulate surrounding cells to produce nerve growth factor, which keeps neurons alive and maintains the axon connections between motor neurons and their target muscles. NGF decline is associated with accelerated neurodegeneration across multiple conditions, and maintaining NGF signaling in motor nerve tissue is a plausible protective mechanism.

BDNF upregulation via erinacines. Brain-derived neurotrophic factor (BDNF) is the primary survival signal for spinal motor neurons, the exact neurons ALS progressively destroys. Erinacines, found in the mycelium of lion's mane, activate BDNF production in brain tissue. A 2025 systematic review by Spangenberg and colleagues examined 27 preclinical studies of erinacines specifically and confirmed consistent BDNF activation as one of the core mechanisms.^[5] For more on BDNF signaling and what lion's mane does to it, see lion's mane and BDNF.

Neurotrophin-3 (NT-3) activation. Fast-fatiguable motor neurons, the specific motor neuron subtype that ALS preferentially destroys in its earliest stages, depend more on NT-3 signaling for their survival than other subtypes. This makes NT-3 the most ALS-specific of the three neurotrophin findings. Spangenberg et al. documented NT-3 activation through erinacine mechanisms across multiple preclinical models.^[5]

Anti-inflammatory effects on microglia. In ALS, the brain's immune cells shift into a damaging overactivated state and release inflammatory signals that kill motor neurons. This neuroinflammatory cascade drives a substantial portion of motor neuron death and accelerates disease progression. Szućko-Kociuba et al. documented reduction of neuroinflammatory signaling proteins by lion's mane compounds in neural tissue models.^[2]

Antioxidant and anti-apoptotic protection. The oxidative damage caused by impaired SOD1 function, and the toxic TDP-43 protein clumps that generate reactive oxygen species as they accumulate, can be countered by the antioxidant pathways lion's mane activates in non-ALS models. Lion's mane also blocks the apoptotic signaling that executes programmed motor neuron death.^[2]

No single mechanism explains lion's mane's preclinical neuroprotective profile. The significance is that the combination maps directly onto the ALS pathological process, which is why the ALS research community considers the theoretical case plausible rather than speculative, even in the absence of ALS-specific data.

Erinacines vs. Hericenones: Why the Specific Compound Determines Whether Effects Reach the Brain

Not all lion's mane compounds work the same way, and the distinction between hericenones and erinacines matters specifically for any central nervous system effect, including motor neuron protection in the spinal cord.

Hericenones are found in the fruiting body of lion's mane. They stimulate NGF production in peripheral tissue. But they do not cross the blood-brain barrier (the selective filter that prevents most substances from passing from the bloodstream into brain tissue) with any established efficiency. For peripheral nerve effects, hericenones are relevant. For effects in the brain or spinal cord, where ALS destroys motor neurons, hericenones face a fundamental limitation.

Erinacines are structurally different. Found almost exclusively in lion's mane mycelium, they do cross the blood-brain barrier. Once inside the central nervous system, they activate BDNF, NGF, and NT-3 production directly in brain and spinal cord tissue, the precise location where motor neuron protection would need to occur in ALS.^[5]

Spangenberg et al.'s 2025 systematic review was designed specifically to separate the erinacine evidence from the broader lion's mane literature, because hericenones and erinacines are routinely conflated in supplement marketing and some research papers. Across 27 preclinical studies, erinacines showed consistent neurotrophin activation, neuroprotective effects, and reduced neuroinflammation in central nervous system models.^[5]

For anyone evaluating lion's mane products for neurological purposes, the relevant question is whether a product contains erinacines (which requires mycelium) or primarily hericenones (fruiting body). The research supporting central nervous system neurotrophin activation is specifically the erinacine research. For more on how erinacines cross the blood-brain barrier, see erinacines: the compounds that cross the blood-brain barrier.

Peripheral Nerve Regeneration: Where Lion's Mane Motor Nerve Evidence Is Actually Strongest

ALS destroys motor neurons in the brain and spinal cord. But it also progressively damages the physical connections between those neurons and the muscles they control, including the peripheral junctions where movement commands are ultimately delivered to muscle fibers. This peripheral damage component is where lion's mane has its most direct existing evidence for motor nerve tissue.

A 2012 review by Wong and colleagues in the International Journal of Medicinal Mushrooms examined lion's mane's ability to promote peripheral nerve regeneration across multiple animal models of peripheral nerve injury.^[4] The mechanism is NGF-driven: lion's mane stimulates the growth of new axon branches from damaged nerves and promotes remyelination, the restoration of the insulating sheath that allows electrical signals to travel efficiently along nerve fibers.

The peripheral nerve regeneration evidence is more established and more directly demonstrated than the central motor neuron protection evidence. Multiple preclinical studies support it across different peripheral nerve injury models. Whether lion's mane's peripheral nerve effects slow the neuromuscular junction deterioration that contributes to muscle weakness and atrophy in ALS has not been tested specifically, but the biology is plausible.

The honest distinction: lion's mane's evidence is stronger for peripheral motor nerve tissue than for spinal cord motor neurons, which are ALS's primary target. Whether peripheral effects would translate to clinically meaningful benefit in ALS is an open question that requires ALS-specific study to answer.

How Alzheimer's and Parkinson's Models Frame the ALS Research Gap

The absence of ALS in lion's mane research reflects a research funding reality, not a mechanistic mismatch. ALS affects roughly 30,000 Americans at any given time, a fraction of the 6 million with Alzheimer's disease. Rare disease research attracts proportionally less funding, fewer research laboratories, and far fewer registered clinical trials.

A 2023 review by Brandalise and colleagues in the Journal of Fungi examined the full clinical and preclinical evidence for lion's mane across neurodegenerative conditions: Alzheimer's, Parkinson's, stroke, and depression.^[3] Their review found meaningful preclinical evidence in Alzheimer's models, sufficient to motivate clinical trials that have since followed, and growing preclinical evidence in Parkinson's models. ALS was absent from the evidence base entirely. Not because researchers investigated and found no effect, but because no one has yet studied it.

The mechanistic connection between these diseases and ALS is direct. Alzheimer's, Parkinson's, and ALS all involve oxidative stress damage to neurons, neuroinflammation driven by overactivated microglia, impaired clearance of misfolded proteins, and mitochondrial failure. Lion's mane addresses all of these pathways in the diseases that have been studied. The same pathways are equally disrupted in ALS.

The Brandalise 2023 review's subtitle, "how far from the shoreline?", is an apt description of lion's mane's position for all neurological indications. The preclinical work is real. The clinical translation remains incomplete, and for ALS, even the preclinical work hasn't begun. For related research on the Parkinson's mechanistic overlap, see mushrooms and Parkinson's disease.

The logical research priority is a preclinical ALS study using erinacines in established ALS mouse models, either the SOD1-G93A transgenic mouse (the most commonly used ALS animal model) or TDP-43 transgenic mice that model the more common TDP-43 pathological form of the disease. Erinacines, with their documented ability to cross into the central nervous system and activate motor neuron survival pathways, are the specific lion's mane fraction most worth testing first. No such study is currently registered in ALS research databases. For the broader picture of mushroom compounds beyond lion's mane that show motor neuron disease relevance, see mushroom compounds and motor neuron protection and mushroom neuroprotection in ALS.

The Bottom Line

The 2024 ALSUntangled review confirmed that lion's mane has not been tested in any ALS model. The mechanisms are real and documented in non-ALS preclinical models: NGF, BDNF, and neurotrophin-3 activation through erinacines; anti-inflammatory and antioxidant effects through hericenone and polysaccharide pathways. Peripheral nerve regeneration evidence is the strongest existing data for lion's mane and motor nerve tissue. ALS-specific research remains absent, and the current evidence does not support recommending lion's mane for ALS. The mechanistic rationale for a preclinical research program is clear.

Frequently Asked Questions

Does lion's mane help with ALS?

No ALS-specific research on lion's mane exists in any model: cell culture, animal, or human. The 2024 ALSUntangled review found the mechanisms are theoretically relevant (NGF, BDNF, anti-inflammatory, antioxidant pathways all align with ALS pathology), but the absence of ALS-specific evidence means there is no data to support recommending it for ALS. Research in Alzheimer's and Parkinson's models provides indirect mechanistic support, and peripheral nerve regeneration evidence is the strongest motor nerve data available.

Can lion's mane regenerate motor neurons?

Lion's mane has shown regenerative effects on peripheral motor nerves in animal models, promoting new axon growth and remyelination through NGF stimulation, per a 2012 review by Wong et al. Central motor neurons in the spinal cord and brainstem, which ALS destroys, have not been specifically tested. Erinacines activate neurotrophins that support central motor neuron survival in non-ALS preclinical models, but whether those effects translate to regeneration in ALS-damaged motor neurons is unknown.

What does lion's mane do for nerves?

In preclinical models, lion's mane stimulates three neurotrophins that support nerve survival and function: nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin-3 (NT-3). It reduces neuroinflammation in neural tissue, shows antioxidant effects relevant to nerve damage, and blocks programmed neuron death. Erinacines from the mycelium drive the central nervous system neurotrophin effects; hericenones from the fruiting body drive peripheral NGF stimulation. Peripheral nerve regeneration evidence from animal injury models is stronger than central nervous system evidence.

Has lion's mane been tested in ALS models?

No. The 2024 ALSUntangled review in the ALS specialty journal found no studies of lion's mane in ALS cell lines, ALS animal models, or ALS patients. Lion's mane promotes NGF, BDNF, and neurotrophin-3 in non-ALS preclinical models, all neurotrophins that support motor neuron survival, making it theoretically relevant but unproven for ALS specifically. An ALS preclinical study using erinacines in SOD1-G93A or TDP-43 transgenic mice would be the logical next research step.

What does ALSUntangled say about lion's mane?

ALSUntangled reviewed lion's mane in 2024, published in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. Their verdict: theoretically plausible (several mechanisms align with ALS pathology including NGF stimulation, anti-inflammatory effects, and antioxidant activity), no ALS-specific evidence in any model, appears safe. They concluded there is not enough evidence to recommend lion's mane for ALS, and that ALS-specific preclinical research is the appropriate next step.

Sources & References

1. 1RTHM-00896·Muhanna, Maya et al. (2024). “ALSUntangled #73: Lion's Mane..” Amyotrophic lateral sclerosis & frontotemporal degeneration.Study breakdown →PubMed →↩
2. 2RTHM-01798·Szućko-Kociuba, Izabela et al. (2023). “Neurotrophic and Neuroprotective Effects of Hericium erinaceus..” International journal of molecular sciences.Study breakdown →PubMed →↩
3. 3RTHM-01662·Brandalise, Federico et al. (2023). “Hericium erinaceus in Neurodegenerative Diseases: From Bench to Bedside and Beyond, How Far from the Shoreline?.” Journal of fungi (Basel.Study breakdown →PubMed →↩
4. 4RTHM-00500·Wong, Kah-Hui et al. (2012). “Neuroregenerative potential of lion's mane mushroom, Hericium erinaceus (Bull.: Fr.) Pers. (higher Basidiomycetes), in the treatment of peripheral nerve injury (review)..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
5. 5RTHM-02184·Spangenberg, E T et al. (2025). “Unveiling the role of erinacines in the neuroprotective effects of Hericium erinaceus: a systematic review in preclinical models..” Frontiers in pharmacology.Study breakdown →PubMed →↩